High-grade serous ovarian cancer, the most common form of the disease, is often fatal. This study investigated the genomic and immune characteristics of tumors from women who survived more than 10 ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

The big question thrown up in the results, however, is the role of Imfinzi, given that PD-1/PD-L1 checkpoint inhibitors have until now largely failed to move the needle in advanced ovarian cancer ...